Enliven Therapeutics ELVN Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's operating income?
- Enliven Therapeutics (ELVN) reported operating income of -$27.82M in Q1 2026.
- How has Enliven Therapeutics's operating income changed year-over-year?
- Enliven Therapeutics's operating income increased by 12.2% year-over-year, from -$31.69M to -$27.82M.
- What is the long-term trend for Enliven Therapeutics's operating income?
- Over 4 years (2021 to 2025), Enliven Therapeutics's operating income has grown at a 23.5% compound annual growth rate (CAGR), from -$51.44M to -$119.66M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.